KAIYUAN SECURITIES·2026-03-01 07:58Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights that the price adjustment by Laopu Gold exceeded expectations, reinforcing its high-end brand positioning. The price increase for most products ranged from 20% to 30%, significantly higher than previous adjustments [5][27] - The report emphasizes the shift in consumer demand towards self-wearing and aesthetic-driven purchases, suggesting that brands with differentiated product offerings are likely to navigate price increases more smoothly [31] Summary by Sections Industry Trends - The retail and social service indices reported a decline of 1.64% and an increase of 1.68% respectively during the week from February 24 to February 27, 2026. The retail index ranked 30th among 31 primary industries [7][16] - The jewelry sector has shown the highest growth, with a year-to-date increase of 10.59% [19] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Laopu Gold and Chaohongji, with beneficiaries including Liu Fu Group and Zhou Shengsheng [8][33] - Investment Theme 2: Highlighting retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [8][33] - Investment Theme 3: Emphasizing beauty brands that meet emotional value and safety ingredient innovation, recommending Maogeping and Pola [8][33] - Investment Theme 4: Focusing on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [8][33] Company-Specific Insights - Laopu Gold reported a revenue of 12.354 billion yuan for the first half of FY2025, a year-on-year increase of 250.9%, with a net profit of 2.268 billion yuan, up 285.8% [35] - Chaohongji is expected to achieve a net profit of 436 to 533 million yuan in 2025, reflecting a growth of 125% to 175% [35] - Yonghui Supermarket is projected to have a net profit of -2.14 billion yuan in 2025, indicating a significant operational challenge [35] - Meilitiantian Medical Health anticipates a net profit growth of no less than 34% in 2025, showcasing strong resilience and potential for growth [43]